The estimated Net Worth of Jerome D Jabbour is at least 4.15 百万$ dollars as of 17 March 2020. Mr. Jabbour owns over 10,000 units of Matinas Biopharma Inc stock worth over 2,826,271$ and over the last 7 years he sold MTNB stock worth over 0$. In addition, he makes 1,325,180$ as President、 Chief Executive Officer、 Director at Matinas Biopharma Inc.
Sign up
Mr. Jabbour MTNB stock SEC Form 4 insiders trading
Jerome has made over 3 trades of the Matinas Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of MTNB stock worth 6,500$ on 17 March 2020.
The largest trade he's ever made was buying 14,650 units of Matinas Biopharma Inc stock on 19 August 2019 worth over 9,962$. On average, Jerome trades about 2,857 units every 21 days since 2018. As of 17 March 2020 he still owns at least 799,511 units of Matinas Biopharma Inc stock.
You can see the complete history of Mr. Jabbour stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jerome Jabbour biography
Jerome D. Jabbour J.D. serves as President, Chief Executive Officer, Director of the Company. Mr. Jabbour was appointed Chief Executive Officer in March 2018. He has served as our President since March 2016. Prior to that he served as our Executive Vice President, Chief Business Officer, General Counsel and Secretary since October 2013 and as one of our directors from April 2012 until November 2013. Mr. Jabbour is also a Co-founder of Matinas BioPharma. Prior to joining our management team, he was the Executive Vice President and General Counsel of MediMedia USA, or MediMedia, from 2012 to October 2013, a privately held diversified health care services company. Prior to MediMedia, he was the Senior Vice President, Head of Global Legal Affairs of Wockhardt Limited (2008-2012) and Senior Counsel and Assistant Secretary at Reliant (2004-2008). Earlier in his career, he held positions as Commercial Counsel at Alpharma, Inc. (2003-2004) and as a Corporate Associate at Lowenstein Sandler LLP (1999-2003). Mr. Jabbour earned his J.D. from Seton Hall University School of Law in New Jersey and a B.A. in Psychology from Loyola University in Baltimore.
What is the salary of Jerome Jabbour?
As the President、 Chief Executive Officer、 Director of Matinas Biopharma Inc, the total compensation of Jerome Jabbour at Matinas Biopharma Inc is 1,325,180$. There are no executives at Matinas Biopharma Inc getting paid more.
How old is Jerome Jabbour?
Jerome Jabbour is 45, he's been the President、 Chief Executive Officer、 Director of Matinas Biopharma Inc since 2018. There are 16 older and no younger executives at Matinas Biopharma Inc. The oldest executive at Matinas Biopharma Holdings Inc is Herbert Conrad, 87, who is the Independent Chairman of the Board.
What's Jerome Jabbour's mailing address?
Jerome's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER, NJ, 07921.
Insiders trading at Matinas Biopharma Inc
Over the last 8 years, insiders at Matinas Biopharma Inc have traded over 0$ worth of Matinas Biopharma Inc stock and bought 1,157,037 units worth 1,139,222$ . The most active insiders traders include Patrick G Lepore、Adam K Stern、James S Scibetta. On average, Matinas Biopharma Inc executives and independent directors trade stock every 40 days with the average trade being worth of 187,938$. The most recent stock trade was executed by Adam K Stern on 21 August 2020, trading 20,000 units of MTNB stock currently worth 16,600$.
What does Matinas Biopharma Inc do?
matinas biopharma (nyse mkt: mtnb) is a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications. the company's proprietary, disruptive technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. the company's lead drug candidate mat2203, currently in phase 2, is an orally-administered, encochleated formulation of amphotericin b (a broad spectrum fungicidal agent). the company has an open investigational new drug (ind) application for mat2501, currently in phase 1, which is an orally-administered, encochleated formulation of amikacin (a broad spectrum aminoglycoside antibiotic agent) for acute bacterial infections, including non-tuberculous mycobacterium (ntm) and multi-drug resistant gram negative bacterial infections. the company's lead anti-infective product candidates, mat2203 and mat2501, position matinas biopharma to bec
What does Matinas Biopharma Inc's logo look like?
Complete history of Mr. Jabbour stock trades at Matinas Biopharma Inc
Matinas Biopharma Inc executives and stock owners
Matinas Biopharma Inc executives and other stock owners filed with the SEC include:
-
Jerome Jabbour,
President, Chief Executive Officer, Director -
Keith Kucinski,
Chief Financial Officer -
James Ferguson,
Chief Medical Officer -
Jerome D. Jabbour J.D.,
Co-Founder, CEO, Pres & Director -
Theresa Matkovits,
Chief Development Officer -
Dr. James J. Ferguson FACC, M.D.,
Chief Medical Officer -
Dr. Theresa Matkovits Ph.D.,
Chief Devel. Officer -
Raphael Mannino,
Chief Scientific Officer -
Ian Cooney,
Director ,Investor Relations & Corporate Development -
Matthew Wikler,
Independent Director -
James Scibetta,
Independent Director -
Natasha Giordano,
Independent Director -
Eric Ende,
Independent Director -
Patrick LePore,
Independent Vice Chairman of the board -
Herbert Conrad,
Independent Chairman of the Board -
Thomas J. Hoover M.B.A.,
Chief Bus. Officer -
Frank Calamusa,
Exec. Director and Head of Manufacturing & Supply Chain -
Dr. Raphael J. Mannino Ph.D.,
Chief Scientific Officer -
Dr. Hui Liu M.B.A., Ph.D.,
Chief Technology Officer -
Keith A. Kucinski CPA, M.B.A.,
Chief Financial Officer -
Adam K Stern,
Director -
Dominick Di Paolo,
Senior VP of Compliance -
Gary Gaglione,
Chief Financial Officer -
Roelof Rongen,
Chief Executive Officer -
Jennifer Gjg Life Sciences,...,
-
Stefano Ferrari,
Director -
Hui Liu,
Chief Technology Officer -
Kathryn Penkus Corzo,
Director -
Thomas Hoover,
Chief Business Officer